ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $102.1429.

Several equities research analysts recently issued reports on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. lifted their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. HC Wainwright boosted their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th.

Check Out Our Latest Research Report on ANI Pharmaceuticals

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director owned 25,157 shares in the company, valued at $2,041,490.55. This represents a 6.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Meredith Cook sold 400 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $82.32, for a total value of $32,928.00. Following the completion of the sale, the vice president directly owned 74,874 shares in the company, valued at $6,163,627.68. This represents a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 28,001 shares of company stock valued at $2,446,934. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Balyasny Asset Management L.P. raised its holdings in shares of ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth $21,454,000. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $76.28 on Tuesday. The company’s 50 day simple moving average is $82.81 and its 200-day simple moving average is $83.17. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals has a 1 year low of $52.74 and a 1 year high of $99.50. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 46.80 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Read More